Mirae Asset Global Etfs Holdings Ltd. Bei Gene, Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 4,921 shares of BGNE stock, worth $970,470. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,921Holding current value
$970,470% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.5MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.08 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.38 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.02 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$983 Million0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$726 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...